Distribution of company announcements to the professional platforms, finance portals and syndication of important corporate news to a wide variety of news aggregators and financial news systems.
MediGene AG (FRA:MDG) Corporate news announcement processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------
Live webcast of the presentation at the Rodman & Renshaw Healthcare Conference on November 10, 2008 available at www.medigene.com
Martinsried/Munich, November 06, 2008. MediGene AG (Frankfurt, Prime Standard: MDG) will be presenting at the Rodman & Renshaw Healthcare Conference in New York on November 10, 2008 at 5:45pm (11:45pm CET). Dr. Peter Heinrich, Chief Executive Officer of MediGene AG, will give a review of the company and update the audience on recent business developments. The presentation will be webcast live, and a replay will also be available at www.medigene.com.
In addition, Dr. Thomas Klaue, Financial Chief Officer of MediGene AG, will present a review of the company on November 11, at 12.45pm local time, at the German Equity Forum in Frankfurt.
MediGene is the first German biotech company to have drugs on the market, which are being distributed by partner companies. MediGene has several drug candidates in clinical development, including EndoTAG(TM)-1 which could offer substantial sales returns. In addition, the company has numerous projects in research and pre-clinical development and possesses innovative platform technologies. MediGene focuses on the research and development of novel drugs for the treatment of cancer and autoimmune diseases.
This press release contains forward-looking statements representing the opinion of MediGene as of the date of this release. The actual results achieved by MediGene may differ significantly from the statements made herein. MediGene is not bound to update any of these forward-looking statements. EndoTAG(TM) and MediGene® are trademarks of MediGene AG, This trademark may be owned or licensed in selected locations only.
- ends -
MediGene AG is a publicly listed (Frankfurt, Prime Standard: MDG) biotechnology company located in Martinsried/Munich, Germany, with subsidiaries in Oxford, UK and San Diego, USA.
Contact MediGene AG E-mail: investor@medigene.com Fax:++49 - 89 - 85 65 - 2920 Julia Hofmann / Dr. Nadja Wolf, Public Relations, Tel.: ++49 - 89 - 85 65 - 3324 Dr. Georg Dönges, Investor Relations, Tel.: ++49 - 89 - 85 65 - 2946
--- End of Message ---
MediGene AG Lochhamer Strasse 11 Martinsried / München Germany
WKN: 502090; ISIN: DE0005020903 ; Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Düsseldorf, Freiverkehr in Börse Stuttgart, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Niedersächsische Börse zu Hannover, Geregelter Markt in Frankfurter Wertpapierbörse;
